Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.64 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11290860 | 0.87 | CA2 (0.80) | CA2CES2CES1ALDH1A1KDM4E | |
| SCHEMBL31629316 | 0.82 | CA2 (0.59) | CA2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL512650 | 0.81 | CA2 (0.64) | CA2MEN1KMT2A | |
| SCHEMBL19307821 | 0.80 | CA2 (0.70) | CA2KMT2A | |
| SCHEMBL23582819 | 0.78 | CA2 (0.67) | CA2ALDH1A1TSHR | |
| SCHEMBL219773 | 0.78 | CA2 (0.62) | CA2CES2CES1ALDH1A1KDM4E | |
| SCHEMBL6632816 | 0.78 | CA2 (0.67) | CA2ALDH1A1KDM4E | |
| SCHEMBL4242578 | 0.78 | CA2 (0.67) | CA2 | |
| SCHEMBL1272988 | 0.78 | CA2 (0.67) | CA2TSHR | |
| SCHEMBL658518 | 0.78 | CA2 (0.67) | CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025129168-A1 | TRIAZOLONE INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE AND THEIR THERAPEUTIC USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-06-19 | — | — | WO | disclosed |
| EP-4561993-A1 | INHIBITORS OF PLASMA KALLIKREIN | Rezolute, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| CN-120051460-A | Plasma kallikrein inhibitors | 瑞泽路特有限公司 | 2025-05-27 | — | — | CN | disclosed |
| WO-2024025907-A1 | INHIBITORS OF PLASMA KALLIKREIN | REZOLUTE, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2022108980-A1 | PROTEIN AND LIPID THERAPEUTIC TARGETS | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-05-27 | — | — | WO | disclosed |
| EP-3049391-B1 | INDOLE AND INDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2018-12-26 | — | — | EP | disclosed |
| US-9708259-B2 | Indol and indazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160207885-A1 | INDOL AND INDAZOL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-07-21 | — | — | US | disclosed |
| US-20150057433-A1 | PREPARATION OF FUNCTIONALIZED POLYPEPTIDES, PEPTIDES, AND PROTEINS BY ALKYLATION OF THIOETHER GROUPS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-02-26 | — | — | US | disclosed |
| US-20120220635-A1 | AMINOETHYLAROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2012-08-30 | — | — | US | disclosed |
| US-8232426-B2 | N-[4-((S)-2-Propylamino-propyl)-phenyl]-4-trifluoromethoxy-benzenesulfonamide; Dipropyl-{2-[4-(4-trifluoromethoxy-benzenesulfonylmethyl)-phenyl]-ethyl}-dipropyl-amine salt, psychological, nervous system disorders such as schizophernia, bipolar, dyskinesias, tourette syndrome, depression, sleep disorder | ABBOTT GMBH & CO. KG (DE) | 2012-07-31 | — | — | US | disclosed |
| EP-1809597-B1 | AMINOETHYLAROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2012-01-11 | — | — | EP | disclosed |
| EP-2371814-A1 | Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | Abbott GmbH & Co. KG (DE) | 2011-10-05 | — | — | EP | disclosed |
| US-20080096934-A1 | Aminoethylaromatic Compounds Suitable For Treating Disorders That Respond To Modulation Of The Dopamine D3 Receptor | ABBOTT GMBH & CO. KG (DE) | 2008-04-24 | — | — | US | disclosed |
| EP-1809597-A1 | AMINOETHYLAROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006040179-A1 | AMINOETHYLAROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2006-04-20 | — | — | WO | disclosed |
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | MCHR2, MCHR1, NPY1R | CA2 952/4885CES2 1380/4885CES1 1863/4885 |
| US-20150057433-A1 | PREPARATION OF FUNCTIONALIZED POLYPEPTIDES, PEPTIDES, AND PROTEINS BY ALKYLATION OF THIOETHER GROUPS | PTMS, TMT1A, PTMA | CA2 4718/4885CES2 1941/4885CES1 1955/4885 |
| US-20080096934-A1 | Aminoethylaromatic Compounds Suitable For Treating Disorders That Respond To Modulation Of The Dopamine D3 Receptor | MC3R, DRD3, ADORA3 | CA2 1742/4885CES2 873/4885CES1 2297/4885 |
| US-20120220635-A1 | AMINOETHYLAROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | SLC6A3, ADRB3, DRD3 | CA2 3395/4885CES2 1146/4885CES1 2986/4885 |
| US-20160207885-A1 | INDOL AND INDAZOL DERIVATIVES | CHRNA7, CHRM1, CHRNA3 | CA2 885/4885CES2 654/4885CES1 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.